Evotec SE, Hamburg, Germany
NOVEL DIRECT ACTING BROAD SPECTRUM
Gram-negative and Gram-positive bacteria
Evotec is developing a novel broad-spectrum antibiotic with both Gram-positive and Gram-negative coverage for indications including complicated urinary tract, intra-abdominal infections and hospital-acquired pneumonia. The compounds developed within the program engage with two validated antibacterial targets and exhibit a novel mode of action. Evotec’s compounds are the product of a rational drug-design approach and should not be impacted by cross-resistance to current therapies. If proven clinically, this class would offer treatment where few or no options are available. The program was in-licensed from US-biotech Resolute Therapeutics in lead optimization, and Evotec is using its proprietary drug discovery and development platforms to continue clinical development.
Current Development Stage: Lead Optimization
CARB-X Investment: Initial investment of up to $2.91 with potential option payments up to $5.53m.
Initial CARB-X Investment Date: March 1, 2020